Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02644668 · ClinicalTrials.gov registry record · Phase 2
A Study of CK-2127107 in Patients With Spinal Muscular Atrophy
A Phase 2 study, sponsored by Cytokinetics.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
NCT02644668 is a Phase 2 study that has completed, run by Cytokinetics. The registered enrollment target is 70 participants.
The verdict
NCT02644668, a Phase 2 study, has completed, sponsored by Cytokinetics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
Study Summary
This study will evaluate the pharmacodynamic (PD) effect of CK-2127107 (hereafter referred to as reldesemtiv) versus placebo on measures of skeletal muscle function or fatigability in patients with Type II, III, or IV spinal muscular atrophy (SMA).
Interventions
- DRUG Placebo
- DRUG Reldesemtiv 150 mg
- DRUG Reldesemtiv 450 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2016-01-14 |
| Est. Completion | 2018-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02644668
The ClinicalTrials.gov registry entry for NCT02644668 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cytokinetics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02644668 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02644668 about?
NCT02644668 is a clinical study titled "A Study of CK-2127107 in Patients With Spinal Muscular Atrophy". This study will evaluate the pharmacodynamic (PD) effect of CK-2127107 (hereafter referred to as reldesemtiv) versus placebo on measures of skeletal muscle function or fatigability in patients with Type II, III, or IV spinal muscular atrophy (SMA).
What is the current status of trial NCT02644668?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2016-01-14. Estimated completion is 2018-05-31.
What interventions are being tested in trial NCT02644668?
The interventions under investigation include: Placebo (DRUG), Reldesemtiv 150 mg (DRUG), Reldesemtiv 450 mg (DRUG).
Who is sponsoring clinical trial NCT02644668?
This trial is sponsored by Cytokinetics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.